Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

The ASX 300 stock highlights that ~92% of all evaluable patients have a programmed death-ligand 1 (PD-L1) Tumor Proportion ...

Immutep's eftilagimod shows a 17.6-month survival benefit in head and neck cancer. Find out how and why IMMP is continuing to ...

Detailed price information for Flagship Communities Real Estate Investm (MHC-U-T) from The Globe and Mail including charting and trades.

The study by Li et al. provides fundamental findings supported by convincing evidence that they defined cellular reprogramming of androgen receptor in neuroendocrine prostate cancer (NEPC). The ...

Influenza viruses are among the most likely triggers of future pandemics. A research team has developed a method that can be used to study the interaction of viruses with host cells in unprecedented ...

Using advanced proteomics technologies, research teams from the Shanghai Institute of Nutrition and Health at the Chinese ...

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS 1; Mature overall survival ...

"This virus binds to MHC class II complexes -- protein receptors that are typically found on certain immune cells," says Dr. Peter Reuther, research group leader from the Institute of Virology of ...

Credit: Nature Communications (2025). DOI: 10.1038/s41467-025-58834-y "This virus binds to MHC class II complexes—protein receptors that are typically found on certain immune cells," says Dr ...